GlassScriptPhysician profile
Douglas M Gonzales
NPI 1538158951
$3,637.42
in general payments reported to CMS, 2019-2025
26 companies · $587 in 2025
The $587 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $258 · 2021: $260 · 2022: $565 · 2023: $631 · 2024: $708 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $677.37 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Tris Pharma INC | $506.88 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $476.47 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $249.62 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $244.37 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $236.29 | 2019-2025 | |
| Sanofi Pasteur INC. | $224.39 | 2019-2025 | |
| Shire North American Group INC | $136.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.86 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $101.64 | 2022-2024 | Qelbree |
| Adlon Therapeutics L.P. | $83.69 | 2019-2021 | |
| Neos Therapeutics, LP | $77.95 | 2019-2024 | Cotempla Xr-Odt |
| Sobi, INC | $66.15 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $56.64 | 2024-2025 | |
| Rhodes Pharmaceuticals L.P. | $44.07 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.13 | 2024 | Flumist Quadrivalent |
| Phadia US INC. | $39.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $39.47 | 2024-2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $38.99 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $35.12 | 2025 | Voxzogo 1.2mg |
| Kaleo, INC. | $29.94 | 2020-2021 | |
| Aytu Biopharma, INC. | $28.02 | 2022-2023 | Karbinal |
| Hologic Sales and Service, LLC | $28.01 | 2023 | Aptima |
| Seqirus USA INC | $15.84 | 2025 | Fluad, Flucelvax |
| Cumberland Pharmaceuticals, INC. | $15.35 | 2025 | Kristalose |
| Sarepta Therapeutics, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.